Skip to main content

Table 1 Characteristics of the patient cohort with portal hypertension due to advanced chronic liver disease (ACLD), stratified by the presence of clinically significant portal hypertension (CSPH) (cohort ii)

From: Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases

  ACLD (n = 333) No CSPH (n = 53) CSPH (n = 280) P value
Age (years) 54 (15) 55 (14) 54 (15) 0.51
Male sex (n, %) 243 (73) 40 (76) 203 (73) .66
Alcohol (n, %) 119 (36) 6 (11) 113 (40) < .001
Non-alcoholic fatty liver (n, %) 28 (8) 5 (9) 23 (8)
Viral (n, %) 141 (42) 38 (72) 103 (37)
Child-Pugh score (points) 6 (3) 5 (0) 7 (4) < .001
MELD score (points) 10 (5) 8 (2) 11 (5) < .001
ALT (U/L) 41 (51) 61 (66) 40 (46) .001
AST (U/L) 59 (53) 60 (52) 58 (53) .97
Bilirubin (mg/dL) 1.1 (1.1) 0.6 (0.4) 1.2 (1.3) < .001
Albumin (g/L) 36.7 (8.3) 40.5 (4.2) 35.7 (7.9) < .001
INR 1.20 (0.30) 1.10 (0.18) 1.30 (0.22) < .001
Creatinine (mg/dL) 0.77 (0.24) 0.87 (0.27) 0.74 (0.23) .001
Platelet count (G/L) 105 (79) 152 (63) 99 (62) < .001
HVPG (mmHg) 17 (10) 8 (2) 18 (7) < .001
CYFRA21-1 (ng/mL) 4.3 (3.3) 3.0 (1.5) 4.6 (3.3) < .001
Liver-related death (n, %) 70 (21) 10 (19) 60 (21) .68
Hepatic decompensation or liver-related death (n, %) 176 (53) 19 (36) 157 (56) .007
  1. Portal hypertension was defined as patients having a hepatic venous pressure gradient (HVPG) ≥ 6 mmHg whereas CSPH was defined as HVPG ≥ 10 mmHg. Quantitative measures are shown as median (interquartile range) or as an absolute count (n) and relative frequency (%). Abbreviations: MELD model of end-stage liver disease, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio